FDA grants accelerated approval to BeOne Medicines’ next-generation BCL2 inhibitor
BeOne Medicines (NASDAQ:ONC) announced that Beqalzi is now authorized for MCL patients who have previously been treated with a Bruton’s tyrosine kinase (BTK) inhibitor.










